Zevra Therapeutics (ZVRA) Surges 12.3%: Is This an Indication of Further Gains?

Core Insights - Zevra Therapeutics (ZVRA) shares increased by 12.3% to close at $11.78, with a notable trading volume, and a total gain of 44.5% over the past four weeks [1][2] Company Performance - The rise in stock price is linked to positive investor sentiment regarding Zevra's growth prospects, particularly due to its drug Miplyffa, which received FDA approval for treating Niemann-Pick disease type C in September 2024, generating $38.6 million in sales during the first half of 2025 [2] - The company is expected to report a quarterly loss of $0.04 per share, reflecting a year-over-year change of +94.2%, with revenues projected at $26.53 million, a significant increase of 619.1% from the previous year [3] - The consensus EPS estimate for the upcoming quarter has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] Industry Context - Zevra Therapeutics is categorized under the Zacks Medical - Drugs industry, which includes other companies like OmniAb, Inc. (OABI), that also experienced a stock increase of 6.2% to $1.71 in the last trading session [5] - OmniAb's consensus EPS estimate for the upcoming report has remained unchanged at -$0.15, representing a year-over-year change of +6.3% [6]